Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 10.00
Open 10.00
Day range 9.77 10.24
52-week range 6.75 24.34
Off day high −4.59%
Off 52-week high −59.86%
Volume 4.53K
Avg. volume (3M) 379
Market cap 1.37B
EPS (TTM) -2.87
Forward P/E -2.85
P/E ratio (TTM) —
Dividend yield —
Beta (5Y) —
Shares outstanding 140.13M
Short interest —
Earnings date Aug 6, 2026 (est.)
Analyst target —
Profit margin —
No recent coverage in the 4Search index.
From articles in the 4Search news index.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat…
From Wikipedia , CC BY-SA 4.0
Earnings
Next report: Thu, Aug 6, 2026 (estimated)
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).
Not eligible for Growth tech (U.S. technology stocks only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use .